scholarly journals 962MO A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells (myDC) in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

2021 ◽  
Vol 32 ◽  
pp. S832-S833
Author(s):  
J.K. Schwarze ◽  
J. Tijtgat ◽  
G. Awada ◽  
L. Cras ◽  
I. Dufait ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase I ◽  
Intratumoral Injection ◽  
Phase I Clinical Trial ◽  
Talimogene Laherparepvec ◽  
Myeloid Dendritic Cells

scholarly journals Safety, feasibility and functionality of activated autologous dendritic cells for intratumoral injection in solid tumors: a Phase I clinical trial

2015 ◽  
Vol 3 (Suppl 2) ◽  
pp. P199
Author(s):  
Vivek Subbiah ◽  
Ravi Murthy ◽  
David Hong ◽  
Robert Prins ◽  
Chitra Hosing ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase I ◽  
Solid Tumors ◽  
Intratumoral Injection ◽  
Phase I Clinical Trial

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: Results of a phase I clinical trial

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 2551-2551
Author(s):  
A. Meye ◽  
S. Fuessel ◽  
M. Schmitz ◽  
S. Zastrow ◽  
C. Linne ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Dendritic Cells ◽  
T Cell ◽  
Phase I ◽  
T Cell Activation ◽  
T Cell Response ◽  
Phase I Clinical Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

2551 Background: For patients with hormone-refractory prostate cancer (HRPC) treatment options are limited. Immunotherapies based on dendritic cells (DCs) might represent promising alternatives. In a Phase I clinical trial, we evaluated the safety and feasibility of a vaccination with monocyte-derived DCs loaded with a cocktail consisting of HLA-A*0201-restricted peptides derived from prostate cancer-associated antigens (PSA, PSMA, survivin, prostein, trp-p8). Methods: Eight HRPC patients were enrolled in this study (Table). Each patient underwent two leukaphereses, for the isolation of monocytes and subsequent generation of mature DCs. Patients received a total of four vaccinations each with peptide cocktail-loaded DCs at a dose of 1 x 107 cells both intradermally and intravenously every other week. Clinical response was monitored by the determination of the PSA level. The induction of a peptide-specific T-cell response was assessed by ELISPOT analysis. Results: Apart from local erythema and edema at the site of intradermal administration no side effects were noted. Four of eight patients showed a temporary PSA decline. One patient displayed a partial response with a PSA decrease > 50% for seven weeks and further stabilization for five weeks. Stable PSA values or decelerated PSA increases were observed in the three remaining patients. In ELISPOT analyses, three of four PSA responders also showed antigen-specific CD8+ T-cell activation against prostein, survivin and PSMA. Conclusions: The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa. [Table: see text] [Table: see text]

scholarly journals A Double-Blind Randomized Phase I Clinical Trial Targeting ALVAC-HIV Vaccine to Human Dendritic Cells

PLoS ONE ◽  
2011 ◽  
Vol 6 (9) ◽  
pp. e24254 ◽  
Author(s):  
Michael A. Eller ◽  
Bonnie M. Slike ◽  
Josephine H. Cox ◽  
Emil Lesho ◽  
Zhining Wang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dendritic Cells ◽  
Phase I ◽  
Hiv Vaccine ◽  
Phase I Clinical Trial ◽  
Double Blind ◽  
Human Dendritic Cells
Sign in / Sign up

Export Citation Format

Share Document